MGH/Harvard Study: Assessment of Glutamatergic Neurosystem in Fragile X Syndrome for Targeted Therapy

Nick and attendee
MGH/Harvard is recruiting adult males with Fragile X Syndrome, 18 years or older, for a neuroimaging study. Participants will be compensated up to $350.
 
The aim of the study is to examine problems with a chemical messenger called glutamate in the brain in Fragile X Syndrome, and how it impacts sensory, motor and cognitive abilities and implicated structural and functional connectivity.
 
Three visits at Massachusetts General Hospital are required:
  • Medical history and behavioral testing (approx. 1.5 hours)
  • PET-MRI (approx. 2 hours)
  • Magnetoencephalography (approx. 1 hour).

The study started on March 15, 2018, and ends by June 30, 2020. The IRB approval number is 2017P001039.

Travel/time subsidy: compensation up to $350 for participation.

If you are interested, please contact:

Maria Mody, PhD
maria@nmr.mgh.harvard.edu
617-726-6913